BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15015594)

  • 1. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.
    Gabrielsson S; Brichard V; Dhellin O; Dorval T; Bonnerot C
    Anticancer Res; 2004; 24(1):171-7. PubMed ID: 15015594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
    Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
    Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
    Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients.
    Scheibenbogen C; Lee KH; Mayer S; Stevanovic S; Moebius U; Herr W; Rammensee HG; Keilholz U
    Clin Cancer Res; 1997 Feb; 3(2):221-6. PubMed ID: 9815676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
    Linette GP; Zhang D; Hodi FS; Jonasch EP; Longerich S; Stowell CP; Webb IJ; Daley H; Soiffer RJ; Cheung AM; Eapen SG; Fee SV; Rubin KM; Sober AJ; Haluska FG
    Clin Cancer Res; 2005 Nov; 11(21):7692-9. PubMed ID: 16278389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.
    Whiteside TL; Zhao Y; Tsukishiro T; Elder EM; Gooding W; Baar J
    Clin Cancer Res; 2003 Feb; 9(2):641-9. PubMed ID: 12576430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of the IFN-gamma ELISPOT assay for monitoring CD8(+) T cell response to specific antigen from hepatocellular carcinoma patients].
    Pang X; Shang X; Lü J
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(20):1234-7. PubMed ID: 11825525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
    Peterson AC; Harlin H; Gajewski TF
    J Clin Oncol; 2003 Jun; 21(12):2342-8. PubMed ID: 12805336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
    Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
    Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
    Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
    Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
    J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
    Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
    Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.
    Gervais A; Bouet-Toussaint F; Toutirais O; De La Pintiere CT; Genetet N; Catros-Quemener V
    Anticancer Res; 2005; 25(3B):2177-85. PubMed ID: 16158961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
    Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
    Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.